ArticleResearch synthesis methods2025
Synthesis of depression outcomes reported on different scales: A comparison of methods for modelling mean differences.
Article in Research synthesis methods, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Several methods have been proposed for the synthesis of continuous outcomes reported on different scales, including the Standardised Mean Difference (SMD) and the Ratio of Means (RoM). SMDs can be formed by dividing the study mean treatment effect either by a study-specific (Study-SMD) or a scale-specific (Scale-SMD) standard deviation (SD). We compared the performance of RoM to the different standardisation methods with and without meta-regression (MR) on baseline severity, in a Bayesian network meta-analysis (NMA) of 14 treatments for depression, reported on five different scales. There was substantial between-study variation in the SDs reported on the same scale. Based on the Deviance Information Criterion, RoM was preferred as having better model fit than the SMD models. Model fit for SMD models was not improved with meta-regression. Percentage shrinkage was used as a scale-independent measure with higher % shrinkage indicating lower heterogeneity. Heterogeneity was lowest for RoM (20.5% shrinkage), then Scale-SMD (18.2% shrinkage), and highest for Study-SMD (16.7% shrinkage). Model choice impacted which treatment was estimated to be most effective. However, all models picked out the same three highest-ranked treatments using the GRADE criteria. Alongside other indicators, higher shrinkage of RoM models suggests that treatments for depression act multiplicatively rather than additively. Further research is needed to determine whether these findings extend to Patient- and Clinician-Reported Outcomes used in other application areas. Where treatment effects are additive, we recommend using Scale-SMD for standardisation to avoid the additional heterogeneity introduced by Study-SMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.